Beleave Inc. Share Price Canadian Securities Exchange
Equities
BE
CA0775611084
Pharmaceuticals
Sales 2018 | - | Sales 2019 | 2.37 3.25 197.95 | Capitalization | 30.37M 41.51M 2.53B |
---|---|---|---|---|---|
Net income 2018 | -12M -16.4M -1B | Net income 2019 | -33M -45.11M -2.75B | EV / Sales 2018 | - |
Net cash position 2018 | 5.2M 7.11M 434M | Net Debt 2019 | 10.32M 14.1M 860M | EV / Sales 2019 | 1,71,37,012 x |
P/E ratio 2018 |
-4.72
x | P/E ratio 2019 |
-0.76
x | Employees | - |
Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 98.39% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 26/00/26 | |
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15/15/15 |
Kevin Keagan
BRD | Director/Board Member | - | 24/18/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15/15/15 |
Founder | - | 26/00/26 | |
Kevin Keagan
BRD | Director/Board Member | - | 24/18/24 |
1st Jan change | Capi. | |
---|---|---|
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
+0.09% | 1.65B | |
-7.89% | 1.68B | |
-12.97% | 1.53B | |
+33.40% | 1.38B |